Skip to main content

Table 6 Experimental design and summary of study treatment groups

From: Evaluation of new generation macrolides for the treatment and metaphylaxis of contagious bovine pleuropneumonia (CBPP) in cattle experimentally infected with Mycoplasma mycoides subspecies mycoides

GroupTreatmentDosage (mg/kg), Regimen, RouteCBPP Infection
Kenya (VSRI)/Zambia (CVRI)
Number of Animals Kenya (VSRI)/Zambia (CVRI)aIntubationStart of In-Contact Exposure
Kenya (VSRI)/Zambia (CVRI)
Treatment
Administration
Kenya (VSRI)/
Zambia (CVRI)
Observation Period
Kenya (VSRI)/Zambia (CVRI)
0Nonen/aIntubation with
Afadé/Caprivi strain
60/50Day 08/11 days after intubationn/a49/49 days after intubation
1Saline6.0 mg/kg
Once
SC
In-contact with Group 015/13 (15)n/a8/11 days after intubation41/38 days after start of in-contact exposure92/73 days after treatment
2Tulathromycin2.5 mg/kg
Once
SC
In-contact with Group 015/13 (15)n/a8/11 days after intubation41/38 days after start of in-contact exposure92/73 days after treatment
3Gamithromycin6.0 mg/kg
Once
SC
In-contact with Group 015/13 (15)n/a8/11 days after intubation41/38 days after start of in-contact exposure92/73 days after treatment
4Oxytetracycline20.0 mg/kg
Once
IM
In-contact with Group 015/14 (15)n/a8/11 days after intubation41/38 days after start of in-contact exposure92/73 days after treatment
5Nonen/aIn-contact with Groups 1–420/18 (20)n/a32/28 days after treatment (Groups 1 to 4)n/a60/45 days after co-mingling
  1. aNumbers in brackets indicate the number of animals originally included into the study at CVRI: Seven animals from the combined group were withdrawn for welfare reasons unrelated to CBPP, before the start of the treatment phase and one sentinel was withdrawn before and one after co-mingling for welfare reasons unrelated to CBPP